Immunogenicity and immune privilege of corneal allografts

Chemical Immunology and Allergy

Volumn 92, Issue , 2007, Pages 290-299

  Hori, Junko ^a   Niederkorn, Jerry Y ^b  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ANTERIOR EYE CHAMBER; ARTICLE; CORNEA TRANSPLANTATION; GRAFT REJECTION; GRAFT SURVIVAL; HLA MATCHING; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; INTERMETHOD COMPARISON; KERATOPLASTY; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME; ALLOTRANSPLANTATION; ANIMAL; ANIMAL MODEL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; REVIEW;

ANIMALS; CORNEAL TRANSPLANTATION; HUMANS; IMMUNE TOLERANCE; MODELS, ANIMAL; TRANSPLANTATION, HOMOLOGOUS;

EID: 33947529154     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000099279     Document Type: Article

References (55)

1. Niederkorn JY: Immunology and immunomodulation of corneal transplantation. Int Rev Immunol 2002;21:173-196.
2. Aiken-O'Neill P, Mannis MJ: Summary of corneal transplant activity Eye Bank Association of America. Cornea 2002;21:1-3.
3. Zirm E: Eine erfolgreiche totale Keratoplastik. Graefes Arch Ophthalmol 1906;64:580-593.
4. Niederkorn JY: The immune privilege of corneal grafts. J Leukoc Biol 2003;74:167-171.
5. Auchincloss H Jr, Mayer T, Ghobrial R, Winn HJ: T-cell subsets, bm mutants, and the mechanisms of allogeneic skin graft rejection. Immunol Res 1989;8:149-164.
6. Sonoda Y, Streilein JW: Orthotopic corneal transplantation in mice - evidence that the immunogenetic rules of rejection do not apply. Transplantation 1992;54:694-704.
7. Streilein JW: Immune reguAation and the eye: a dangerous compromise. FASEB J 1987;1:199-208.
8. Streilein JW: OculaT immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003;3:879-889.
9. Niederkorn J: Immune privilege of the eye; in Chen LS (ed): Animal Models of Human Inflammatory Skin Diseases. New York, CRC Press, 2004, p 564.
10. Niederkorn JY: Immune privilege in the anterior chamber of the eye. Crit Rev Immunol 2002;22:13-46.
11. Barker CF, Billingham RE: Immunologically privileged sites. Adv Immunol 1977;25:1-54.
12. Medawar PB: Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948;29:58-69.
13. Streilein JW, McCulley J, Niederkorn JY: Heterotopic corneal grafting in mice: A new approach to the study of corneal alloimmunity. Invest Ophthalmol Vis Sci 1982;23:489-500.
14. Streilein JW, Toews GB, Bergstresser PR: Corneal allografts fail to express Ia antigens. Nature 1979;282:326-327.
15. Wang HM, Kaplan HJ, Chan WC, Johnson M: The distribution and ontogeny of MHC antigens in murine ocular tissue. Invest Ophthalmol Vis Sci 1987;28:1383-1389.
16. Whitsett CF, Stulting RD: The distribution of HLA antigens on human corneal tissue. Invest Ophthalmol Vis Sci 1984;25:519-524.
17. Rubsamen PE, McCulley J, Bergstresser PR, Streilein JW: On the Ia immunogenicity of mouse corneal allografts infiltrated with Langerhans cells. Invest Ophthalmol Vis Sci 1984;25:513-518.
18. Tisher CC, Madsen KM: Anatomy of the kidney. Lymphatics; in Brenner BM (ed): Brenner's and Rector's The Kidney. Philadelphia, Saunders, 1996.
19. Dworkin LD, Brenner BM: The renal circulations; in Brenner BM (ed): Brenner's and Rector's The Kidney. Philadelphia, Saunders, 1996.
20. Foglia RP, DiPreta J, Statter MB, Donahoe PK: Fetal allograft survival in immunocompetent recipients is age dependent and organ specific. Ann Surg 1986;204:402-410.
21. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL: The SCID-hu mouse: Murine model for the analysis of human hematolymphoid differentiation and function. Science 1988;241:1632-1639.
22. Reece-Smith H, Du Toit DF, McShane P, Morris PJ: Prolonged survival of pancreatic islet allografts transplanted beneath the renal capsule. Transplantation 1981;31:305-306.
23. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC: A role for CD95 ligand in preventing graft rejection. Nature 1995;377:630-632.
24. Hori J, Joyce N, Streilein JW: Epithelium-deficient corneal allografts display immune privilege beneath the kidney capsule. Invest Ophthalmol Vis Sci 2000;41:443-452.
25. Hori J, Joyce NC, Streilein JW: Immune privilege and immunogenicity reside among different layers of the mouse cornea. Invest Ophthalmol Vis Sci 2000;41:3032-3042.
26. Khodadoust AA, Silverstein AM: Transplantation and rejection of individual cell layers of the cornea. Invest Ophthalmol 1969;8:180-195.
27. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA: CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997;99:396-402.
28. Yamagami S, Kawashima H, Tsuru T, Yamagami H, Kayagaki N, Yagita H, Okumura K, Gregerson DS: Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation 1997;64:1107-1111.
29. Sano Y, Ksander BR, Streilein JW: Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction. Invest Ophthalmol Vis Sci 1995;36: 2176-2185.
30. Sano Y, Okamoto S, Streilein JW: Induction of donor-specific ACAID can prolong orthotopic corneal allograft survival in 'high-risk' eyes. Curr Eye Res 1997;16:1171-1174.
31. Sonoda Y, Sano Y, Ksander B, Streilein JW: Characterization of cell-mediated immune responses elicited by orthotopic corneal allografts in mice. Invest Ophthalmol Vis Sci 1995;36:427-434.
32. Sonoda A, Sonoda Y, Muramatu R, Streilein JW, Usui M: ACAID induced by allogeneic corneal tissue promotes subsequent survival of orthotopic corneal grafts. Invest Ophthalmol Vis Sci 2000;41:790-798.
33. Yamada J, Streilein JW: Induction of anterior chamber-associated immune deviation by corneal allografts placed in the anterior chamber. Invest Ophthalmol Vis Sci 1997;38:2833-2843.
34. Treseler PA, Foulks GN, Sanfilippo F: The relative immunogenicity of corneal epithelium, stroma, and endothelium. The role of major histocompatibility complex antigens. Transplantation 1986;41: 229-234.
35. Tuberville AW, Foster CS, Wood TO: The effect of donor cornea epithelium removal on the incidence of allograft rejection reactions. Ophthalmology 1983;90:1351-1356.
36. Hori J, Streilein JW: Role of recipient epithelium in promoting survival of orthotopic corneal allografts in mice. Invest Ophthalmol Vis Sci 2001;42:720-726.
37. She SC, Steahly LP, Moticka EJ: A method for performing full-thickness, orthotopic, penetrating keratoplasty in the mouse. Ophthalmic Surg 1990;21:781-785.
38. Williams KA, Coster DJ: Penetrating corneal transplantation in the inbred rat: A new model. Invest Ophthalmol Vis Sci 1985;26:23-30.
39. Sano Y, Ksander BR, Streilein JW: Murine orthotopic corneal transplantation in high-risk eyes. Rejection is dictated primarily by weak rather than strong alloantigens. Invest Ophthalmol Vis Sci 1997;38:1130-1138.
40. Maguire MG, Stark WJ, Gottsch JD, Stulting RD, Sugar A, Fink NE, Schwartz A: Risk factors for corneal graft failure and rejection in the Collaborative Corneal Transplantation Studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology 1994;101: 1536-1547.
41. The Collaborative Corneal Transplantation Studies Research Group: Effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol 1992;110:1392-1403.
42. Volker-Dieben HJ, Kok-van Alphen CC, Lansbergen Q, Persijn GG: Different influences on corneal graft survival in 539 transplants. Acta Ophthalmol (Copenh) 1982;60:190-202.
43. Hori J, Streilein JW: Survival in high-risk eyes of epithelium-deprived orthotopic corneal allografts reconstituted in vitro with syngeneic epithelium. Invest Ophthalmol Vis Sci 2003;44:658-664.
44. Niederkorn JY: The immune privilege of corneal allografts. Transplantation 1999;67:1503-1508.
45. McKinney EC, Streilein JW: On the extraordinary capacity of allogeneic epidermal Langerhans cells to prime cytotoxic T cells in vivo. J Immunol 1989;143:1560-1564.
46. Callanan D, Peeler J, Niederkorn JY: Characteristics of rejection of orthotopic corneal allografts in the rat. Transplantation 1988;45:437-443.
47. He YG, Niederkorn JY: Depletion of donor-derived Langerhans cells promotes corneal allograft survival. Cornea 1996;15:82-89.
48. Sonoda Y, Streilein JW: Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts. J Immunol 1993;150:1727-1734.
49. Skelsey ME, Mellon J, Niederkorn JY: γδ T cells are needed for ocular immune privilege and corneal graft survival. J Immunol 2001;166:4327-4333.
50. Niederkorn JY, Mellon J: Anterior chamber-associated immune deviation promotes corneal allograft survival. Invest Ophthalmol Vis Sci 1996;37:2700-2707.
51. She SC, Steahly LP, Moticka EJ: Intracameral injection of allogeneic lymphocytes enhances corneal graft survival. Invest Ophthalmol Vis Sci 1990;31:1950-1956.
52. Niederkorn JY: The immunology of corneal transplantation. Dev Ophthalmol 1999;30:129-140.
53. Hegde S, Mellon JK, Hargrave SL, Niederkorn JY: Effect of alloantibodies on corneal allograft survival. Invest Ophthalmol Vis Sci 2002;43:1012-1018.
54. Bora NS, Gobleman CL, Atkinson JP, Pepose JS, Kaplan HJ: Differential expression of the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci 1993;34:3579-3584.
55. Lass JH, Walter EI, Burris TE, Grossniklaus HE, Roat MI, Skelnik DL, Needham L, Singer M, Medof ME: Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland. Invest Ophthalmol Vis Sci 1990;31:1136-1148.